CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA

This action is pending in the United States District Court for the Central District of California.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, October 12, 2022

Information

Tags:

American, CNTA, LLC, Register, Lawyer, Company, District court, Lists of schools in England, FREE, Prospectus, GLOBE, Central District, Nasdaq, Security (finance)

Geotags:

ABITA SPRINGS, LA, US, CALIFORNIA, UNITED STATES

Stock Symbol:

NASDAQ:CNTA

Summary

Key Points:

This action is pending in the United States District Court for the Central District of California.
Centessa investors should visit us at https://claimsfiler.com/cases/nasdaq-cnta/ or call toll-free (844) 367-9658.
The case is Fernandes v. Centessa Pharmaceuticals Plc, et al., No.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

NEW ORLEANS, Oct. 11, 2022 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 28, 2022 to file lead plaintiff applications in a securities class action lawsuit against Centessa Pharmaceuticals plc (NasdaqGS: CNTA), if they purchased or otherwise acquired the Company’s securities between May 28, 2021 and June 1, 2022, inclusive (the “Class Period”) and/or purchased or otherwise acquired the Company’s American Depositary Shares (“ADSs”) pursuant to the Company’s May 2021 initial public offering (the “IPO”). This action is pending in the United States District Court for the Central District of California.

Get Help

Centessa investors should visit us at https://claimsfiler.com/cases/nasdaq-cnta/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Centessa and certain of its executives are charged with failing to disclose material information during the Class Period and/or in the Registration Statement and Prospectus issued in conjunction with the initial public offering, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) lixivaptan, the Company’s drug product, was less safe than the Company had represented; (ii) the Company overstated lixivaptan’s clinical effectiveness and commercial viability; (iii) ZF874, another of the Company’s drug products, was less safe than the Company had represented; (iv) the Company overstated ZF874’s clinical effectiveness and commercial viability while downplaying the drug’s safety issues; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

The case is Fernandes v. Centessa Pharmaceuticals Plc, et al., No. 22-cv- 07030.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.